Jeffrey L Cummings

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
  2. ncbi request reprint Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
  3. ncbi request reprint Executive dysfunction in Alzheimer disease
    Margaret M Swanberg
    Department of Neurology, David Geffen School of Medicine at UCLA, 90095 1769, USA
    Arch Neurol 61:556-60. 2004
  4. ncbi request reprint Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
  5. ncbi request reprint Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
  6. ncbi request reprint Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 13:67-73. 2002
  7. ncbi request reprint Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
  8. ncbi request reprint Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
  9. ncbi request reprint Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
  10. ncbi request reprint Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007

Detail Information

Publications68

  1. pmc Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
    ..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
  2. ncbi request reprint Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
    ..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...
  3. ncbi request reprint Executive dysfunction in Alzheimer disease
    Margaret M Swanberg
    Department of Neurology, David Geffen School of Medicine at UCLA, 90095 1769, USA
    Arch Neurol 61:556-60. 2004
    ..Executive dysfunction (EDF) is common in Alzheimer disease (AD); however, its relationship to other symptoms is difficult to assess in patients with AD...
  4. ncbi request reprint Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
    ..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains...
  5. ncbi request reprint Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
    ..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations...
  6. ncbi request reprint Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 13:67-73. 2002
    ..This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine...
  7. ncbi request reprint Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
    ..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions...
  8. ncbi request reprint Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
    ..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration...
  9. ncbi request reprint Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
    ..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD...
  10. ncbi request reprint Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007
    ....
  11. ncbi request reprint Guidelines for managing Alzheimer's disease: part I. Assessment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2263-72. 2002
    ..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease...
  12. ncbi request reprint The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
    ..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
  13. pmc Association of GSK3B with Alzheimer disease and frontotemporal dementia
    Barbara A J Schaffer
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
    Arch Neurol 65:1368-74. 2008
    ..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found...
  14. ncbi request reprint Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies
    Jeffrey L Cummings
    Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 4:57-62. 2007
    ..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents...
  15. ncbi request reprint Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  16. ncbi request reprint Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease
    Jeffrey L Cummings
    UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
    CNS Spectr 13:1-20; quiz 22. 2008
    ..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist...
  17. doi request reprint Biomarkers in Alzheimer's disease drug development
    Jeffrey L Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, NV, USA
    Alzheimers Dement 7:e13-44. 2011
    ..Fit-for-purpose biomarkers are increasingly available to guide AD drug development decisions...
  18. ncbi request reprint Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, USA
    Dement Geriatr Cogn Disord 25:115-26. 2008
    ..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI...
  19. pmc Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
    Arch Neurol 64:1489-95. 2007
    ..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy...
  20. ncbi request reprint Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 24:253-9. 2007
    ..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD...
  21. pmc 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Brain Lang 104:33-41. 2008
    ..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions...
  22. ncbi request reprint Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  23. ncbi request reprint Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 29:406-12. 2010
    ..This was a hypothesis-forming study, designed to provide a basis for possible future research...
  24. doi request reprint Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers
    John M Ringman
    Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 25:380-4. 2008
    ..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)...
  25. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  26. pmc Integrating ADNI results into Alzheimer's disease drug development programs
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
    Neurobiol Aging 31:1481-92. 2010
    ....
  27. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  28. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  29. pmc Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment
    Edmond Teng
    Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 30:189-97. 2010
    ..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices...
  30. pmc Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
    ..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution...
  31. doi request reprint Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Clin Drug Investig 30:41-9. 2010
    ..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD...
  32. doi request reprint Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
    ..Prevention claims will depend heavily on biomarker outcomes...
  33. pmc Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
    Curr Alzheimer Res 6:341-6. 2009
    ..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
  34. pmc Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
    ..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described...
  35. doi request reprint Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
    ....
  36. pmc Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
    ..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly...
  37. ncbi request reprint Deficits in facial emotion processing in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 23:271-9. 2007
    ..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge...
  38. ncbi request reprint ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  39. pmc A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  40. ncbi request reprint Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
    ..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions...
  41. ncbi request reprint Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    N Engl J Med 351:56-67. 2004
  42. ncbi request reprint Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease
    George Bartzokis
    Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
    Neurobiol Aging 25:843-51. 2004
    ..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD...
  43. ncbi request reprint Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  44. ncbi request reprint Relational integration and executive function in Alzheimer's disease
    James A Waltz
    Departjment of Psychology, University of California, Los Angeles, CA 90095 1563, USA
    Neuropsychology 18:296-305. 2004
    ....
  45. ncbi request reprint Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    Mol Genet Metab 80:350-5. 2003
    ..4). These data indicate that evaluation of brain metabolism by PET in appropriately selected patients may improve the accuracy of clinical prognostic assessment...
  46. ncbi request reprint Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease
    Mario F Mendez
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
    Neurology 61:1108-13. 2003
    ..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD...
  47. ncbi request reprint Alzheimer's disease: from molecular biology to neuropsychiatry
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Semin Clin Neuropsychiatry 8:31-6. 2003
    ..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments...
  48. ncbi request reprint Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings
    David L Sultzer
    Departments of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA
    J Neuropsychiatry Clin Neurosci 14:262-9. 2002
    ..These preliminary findings indicate that subcortical MRI hyperintensities may play a role in the pathophysiology and clinical expression of Alzheimer's disease...
  49. ncbi request reprint Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  50. ncbi request reprint Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
    ..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials...
  51. ncbi request reprint Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study
    Jeffrey L Cummings
    University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
    Am J Geriatr Pharmacother 3:137-48. 2005
    ....
  52. ncbi request reprint Behavioral and neuropsychiatric outcomes in Alzheimer's disease
    Jeffrey L Cummings
    Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
    CNS Spectr 10:22-5. 2005
    ....
  53. ncbi request reprint 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 20:224-31. 2006
    ..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance...
  54. ncbi request reprint 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
    ..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool...
  55. ncbi request reprint Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease
    Freddy Ortiz
    The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Am J Alzheimers Dis Other Demen 21:263-73. 2006
    ..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups...
  56. ncbi request reprint Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  57. ncbi request reprint Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
    ..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline...
  58. ncbi request reprint Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
    ..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials...
  59. ncbi request reprint Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
    Po H Lu
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Arch Neurol 63:177-85. 2006
    ..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)...
  60. ncbi request reprint Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia
    George Bartzokis
    Department of Neurology, The David Geffen School of Medicine at UCLA, USA
    Arch Gen Psychiatry 63:63-72. 2006
    ..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD...
  61. ncbi request reprint Neuropathologic correlates of apathy in Alzheimer's disease
    Gad A Marshall
    Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
    Dement Geriatr Cogn Disord 21:144-7. 2006
    ..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology...
  62. ncbi request reprint Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
    Jeffrey L Cummings
    Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Nat Rev Drug Discov 5:64-74. 2006
    ....
  63. ncbi request reprint Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations
    John M Ringman
    UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Brain 130:1767-76. 2007
    ..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...
  64. pmc Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Laboratory of Neuro Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
    Hum Brain Mapp 34:3308-19. 2013
    ..Poorer performing carriers showed greater retrieval period signal, including in the frontal and temporal lobes, suggesting underlying pathological processes...
  65. pmc The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment
    Paula M McLaughlin
    1 Department of Neurology, University of California, Los Angeles, Los Angeles, California
    J Int Neuropsychol Soc 20:402-12. 2014
    ..These findings show that the ability to engage in an effective memory strategy is compromised in aMCI, before AD has developed, suggesting that disruptions in semantic networks are an early marker of the disease. (JINS, 2014, 20, 1-11). ..
  66. pmc Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study
    Liana G Apostolova
    Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 27:174-81. 2013
    ..After correction for baseline hippocampal volume, decline in ADL showed a significant association with right frontal horn enlargement. Executive decline was associated with right frontal and left temporal horn enlargement...
  67. pmc Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, UCLA, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 37:315-26. 2014
    ..Marital status, lower education and race had an effect on selected behaviors. © 2014 S. Karger AG, Basel. ..
  68. pmc Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
    Joshua D Grill
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Neurobiol Aging 34:62-72. 2013
    ..For MCI, the Clinical Dementia Rating scale sum of boxes consistently required the smallest sample sizes. We conclude that predementia clinical trial conduct in Alzheimer's disease is enhanced by the use of biomarker inclusion criteria...